GILD
NASDAQGilead Sciences Inc.
Price$150.88+2.29 (+1.54%)
01:30 PM07:45 PM
News · 26 weeks100-9%
2026-04-052026-09-27
Mix3690d
- Insider18(50%)
- Other10(28%)
- Earnings3(8%)
- SEC Filings3(8%)
- Analyst2(6%)
Latest news
25 items- INSIDERSVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- PRA $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral ThreatNEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can emerge quickly, cross borders and overwhelm healthcare systems before effective therapies are ready. That creates a large and growing commercial opportunity for companies working on drugs that can actually stop viral diseases rather than simply manage their symptoms. The global antiviral drugs market was valued at roughly $42.3 billion in 2025 and is projected to reach approximately $57.8 billion by 2034. But those numbers only tell part of the story. The bigger opportunity may be
- INSIDERChief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChief Medical Officer Berger Dietmar converted options into 533 shares and covered exercise/tax liability with 263 shares, increasing direct ownership by 1% to 19,522 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChief Comm & Corp Aff Officer Mercier Johanna converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 1% to 119,684 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDEREVP Gen Counsel, Legal & Comp Cain Wettan Keeley M converted options into 590 shares and covered exercise/tax liability with 285 shares, increasing direct ownership by 4% to 8,759 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChairman & CEO O'Day Daniel Patrick converted options into 8,780 shares and covered exercise/tax liability with 4,230 shares, increasing direct ownership by 0.79% to 581,683 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- PRGilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines– Brings Together Oncology, Inflammation and Research Data Science Teams to Foster Scientific Collaboration –– One of Three Foster City Projects Supporting Gilead’s $32 Billion U.S. Investment and 3,000 High-Quality Domestic Jobs –Gilead Sciences, Inc. (NASDAQ:GILD) today celebrated the opening of its 182,000-square-foot Research Center at its Foster City headquarters, expanding capabilities in oncology, inflammation and research data science to advance medicines for some of the world’s most challenging diseases. The new Research Center builds on Gilead's longstanding presence in California. Today, Gilead employs approximately 11,000 people across the United States, including more than 7,400
- INSIDERChairman & CEO O'Day Daniel Patrick sold $2,229,592 worth of shares (15,000 units at $148.64) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 577,133 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- FDAFDA Approval for SUNLENCA issued to GILEAD SCIENCES INCSubmission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-17) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 08/27/2026. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy
- FDAFDA Approval for SUNLENCA issued to GILEAD SCIENCES INCSubmission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-24) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 08/27/2026. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy
- INSIDERDirector Welters Anthony exercised 18,000 shares at a strike of $61.06 and sold $2,675,220 worth of shares (18,000 units at $148.62) as part of a pre-agreed trading plan (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- SECSEC Form N-PX filed by Gilead Sciences Inc.N-PX - GILEAD SCIENCES, INC. (0000882095) (Filer)
- PRGilead Sciences to Present at Upcoming Third Quarter 2026 Investor ConferencesGilead Sciences, Inc. (NASDAQ:GILD) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Annual Healthcare Conference on Wednesday, September 9 at 11:00 AM Eastern Time Cantor Global Healthcare Conference on Thursday, September 10 at 10:55 AM Eastern Time Morgan Stanley Global Healthcare Conference on Tuesday, September 15 at 10:45 AM Eastern Time The live webcasts can be accessed at the company’s investors page at investors.gilead.com. The replays will be available for at least 30 days following the presentation. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakth
- PREuropean Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status– European Approval Received for Trodelvy plus Pembrolizumab in First-Line PD-L1-Positive Metastatic Triple-Negative Breast Cancer (TNBC) – – Approval Establishes Trodelvy as the First and Only Antibody-Drug Conjugate for the Treatment of First-Line Metastatic TNBC, Across PD-L1 Status – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab) for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and
- INSIDERDirector Bluestone Jeffrey exercised 5,000 shares at a strike of $67.04 and sold $725,078 worth of shares (5,000 units at $145.02) as part of a pre-agreed trading plan (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChief Financial Officer Dickinson Andrew D sold $415,080 worth of shares (3,000 units at $138.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 165,646 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $67.07 and sold $3,853,908 worth of shares (28,000 units at $137.64) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 118,234 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDEREVP Gen Counsel, Legal & Comp Cain Wettan Keeley M covered exercise/tax liability with 2,908 shares and converted options into 6,002 shares, increasing direct ownership by 58% to 8,454 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- SECSEC Form S-3ASR filed by Gilead Sciences Inc.S-3ASR - GILEAD SCIENCES, INC. (0000882095) (Filer)
- SECSEC Form 10-Q filed by Gilead Sciences Inc.10-Q - GILEAD SCIENCES, INC. (0000882095) (Filer)
- PRCORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial ResultsProduct Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.8 billion Diluted Loss Per Share was $(8.45) and Non-GAAP Diluted Loss Per Share was $(6.75) Reflecting $(9.08) Per Share Acquired IPR&D and Tax Expenses Associated with Recent Acquisitions Please replace the release with the following corrected version due to a change in the "PRODUCT SALES SUMMARY" table, where the Odefsey sales in Europe have been updated to $58 million for the three months ended June 30, 2026 (instead of $28 million). The updated release reads: GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Product Sales Excluding Vekl
- INSIDERChairman & CEO O'Day Daniel Patrick sold $1,954,694 worth of shares (15,000 units at $130.31) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 592,133 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
GILD FAQ
8 questionsWhat does Gilead Sciences Inc. do?
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus...Where does GILD stock trade?
Gilead Sciences Inc. (GILD) is listed on NASDAQ.What sector and industry is GILD in?
Gilead Sciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Gilead Sciences Inc. go public?
Gilead Sciences Inc. (GILD) completed its IPO in 1992.Does GILD pay a dividend?
GILD's most recent ex-dividend date was 2026-09-15 with a cash dividend of $0.82 per share. No future ex-date is on file yet.What are analysts saying about GILD?
Gilead Sciences Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Market Perform on 2026-07-21.What companies are similar to GILD?
Notable peers in the same industry include ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), PFE (Pfizer Inc.), BMY (Bristol-Myers Squibb Company). Compare GILD side-by-side with any of them on Quantisnow.How can I track GILD on Quantisnow?
Quantisnow aggregates Gilead Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GILD to receive live email and push alerts on every new disclosure.